Prelude Therapeutics Incorporated
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Prelude Therapeutics Incorporated generated cash of -$107,063,000, which is less than the previous year. Cash used in financing activities reached the amount of $136,395,000 last year. Net change in cash is therefore -$5,314,000.
Cash Flow
| 2018 | -12.95M | -529K | 17.93M |
|---|---|---|---|
| 2019 | -25.66M | -780K | 29.72M |
| 2020 | -46.17M | -621K | 246.22M |
| 2021 | -83.53M | -263.80M | 164.89M |
| 2022 | -83.72M | 81.69M | 815K |
| 2023 | -107.06M | -34.64M | 136.39M |
PRLD Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 34.64M | 35.87M | 218.30M | 18.87M | 15.59M | 11.14M |
Operating activities | ||||||
Net income | -121.83M | -115.43M | -111.69M | -56.92M | -27.57M | -14.68M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 1.16M | 1.32M | 915K | 542K | 382K | 149K |
Stock-based compensation expense | 25.61M | 25.14M | 20.93M | 5.58M | 846K | 0 |
| Deferred income tax benefit | 25.61M | 25.14M | 20.93M | 5.58M | 846K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -2.27M | -347K | 3.90M | 1.15M | 546K | 721K |
Cash generated by operating activities | -107.06M | -83.72M | -83.53M | -46.17M | -25.66M | -12.95M |
Investing activities | ||||||
Purchases Of Investments | -221.63M | -119.22M | -261.48M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3.51M | -3.01M | -2.32M | -621K | -780K | -529K |
Acquisitions Net | 0 | -84.71K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -34.64M | 81.69M | -263.80M | -621K | -780K | -529K |
Financing activities | ||||||
Common Stock Issued | 135.73M | 389K | 161.42M | 166.63M | 29.85M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -258K | -124K | 0 |
Cash used in financing activities | 136.39M | 815K | 164.89M | 246.22M | 29.72M | 17.93M |
Net Change In Cash | -5.31M | -1.22M | -182.43M | 199.43M | 3.28M | 4.45M |
Cash at end of period | 29.33M | 34.64M | 35.87M | 218.30M | 18.87M | 15.59M |
| Data source | Data source | Data source | Data source |